Strengthening India’s Battle Against Counterfeit Medicinesv

Strengthening India’s Battle Against Counterfeit Medicines

Syllabus:

GS-2: Health, Human Resource, Government Policies & Interventions

Why in the News?

Recent child deaths linked to adulterated cough syrups have reignited debate over India’s regulatory capacity to combat counterfeit medicines and falsified medical products. Experts argue that enforcement under the Drugs and Cosmetics Act (1940) alone is inadequate and call for a multi-agency, forensic-led strategy integrating law enforcement, financial tracking, and inter-departmental coordination to address the growing counterfeit drug market.

India’s Counterfeit Drug Crisis: Scope and Implications

  • Global reputation risk: India, often termed the “Pharmacy of the World,” faces a credibility crisis due to the rise of counterfeit pharmaceutical drugs and substandard products, threatening public health and global trust.
  • Public health threat: Fatal incidents from adulterated cough syrups in several states show systemic regulatory failure, not isolated lapses in pharmaceutical security.
  • Organised criminal networks: The counterfeit medication trade operates through complex, transnational networks linked with money laundering and tax evasion.
  • Weak investigation framework: India’s investigative agencies lack adequate forensic, data-analytic, and intelligence tools to dismantle these networks involved in medicine counterfeiting.
  • Conviction crisis: Conviction rates for counterfeit drug cases hover at below 3%, reflecting severe enforcement gaps in combating falsified medicines.

Key Acts and Institutions

  • Drugs and Cosmetics Act, 1940 – regulates manufacture and sale of medicines.
  • Bharatiya Nyaya Sanhita (BNS), 2023 – replaces IPC; includes cheating, forgery provisions.
  • Prevention of Money Laundering Act (PMLA), 2002 – tracks illicit profits.
  • Supreme Court Judgment (Ashok Kumar, 2020) – limited case registration to drug inspectors.

Institutions Involved:

  • Drug Controller General of India (DCGI) – regulatory authority.
  • National Forensic Sciences University (NFSU) – capacity building for forensic investigation.
  • Enforcement Directorate (ED) – tracks financial crimes.
  • Indian Pharmaceutical Alliance (IPA) – industry association promoting quality standards.

Data Points:

  • Conviction rate for counterfeit drug cases: <3%.
  • India’s pharma exports: $25+ billion annually.
  • Drug inspectors: <2,500, WHO recommends 1 per 200 units.

Global Linkages:

  • India supplies 20% of global generic drugs; counterfeit risks impact trade credibility.
  • WHO estimates 1 in 10 medicines in developing countries is substandard or falsified.

Gaps in the Current Legal and Regulatory Framework

  • Drugs and Cosmetics Act (1940): Originally designed for regulatory compliance, it’s outdated for tackling modern organised crimes like pharmaceutical counterfeiting and drug falsification.
  • Supreme Court restriction: The Ashok Kumar (2020) judgment limited case registration under the D&C Act solely to drug control officers, excluding police intervention in cases of fake medications.
  • Enforcement vacuum: This judicial restriction created a law enforcement paralysis, preventing police from directly acting against counterfeit drug rackets and the broader counterfeit drug market.
  • Legislative mismatch: The Bharatiya Nyaya Sanhita (BNS) and Prevention of Money Laundering Act (PMLA) provide tools against criminal enterprises, but coordination with D&C Act remains weak in addressing counterfeit pharmaceutical drugs.
  • Limited jurisdiction: Drug inspectors focus on regulatory compliance, lacking expertise in criminal investigations or forensic validation of falsified medicines.

Integrating Criminal Law with Drug Regulation

  • Multi-law synergy: The BNS Sections 318, 336-338 (cheating, forgery, falsification of records) can be applied alongside D&C Act provisions to combat counterfeit products in the pharmaceutical supply chain.
  • Judicial precedent: Courts in Delhi, Meerut, Agra, and Dehradun have validated the dual approach, enabling registration of FIRs under both criminal and regulatory laws for cases involving counterfeit medications.
  • Expanding investigative reach: This model empowers police to pursue cheating and forgery angles, exposing larger criminal ecosystems involved in the production and distribution of fake medicine.
  • Accountability through overlap: Joint enforcement ensures dual accountability, covering consumer deception (criminal) and drug quality violations (regulatory) in cases of counterfeit goods.
  • Legal coherence: Harmonising D&C, BNS, and PMLA ensures stronger prosecution and higher conviction probabilities for those involved in the counterfeit drug market.

Multi-Agency Model: Breaking Organised Drug Syndicates

  • Joint investigation teams (SITs): Establish Special Investigation Teams with officers from police, Drug Control Department, Enforcement Directorate, and Forensic Units to tackle counterfeit medicines.
  • Financial tracking: The ED can use PMLA provisions to trace, freeze, and confiscate assets from counterfeit drug profits and disrupt the financial backbone of falsified medical products trade.
  • Tax and billing probes: Income Tax and GST authorities can target fake billing chains and shell companies legitimising illicit profits from counterfeit pharmaceutical drugs.
  • Disrupting financial backbone: By attacking money flows, the government can cripple operational capabilities of counterfeit syndicates involved in medicine counterfeiting.
  • Institutional training: Regular cross-agency training modules can enhance understanding of pharmaceutical crime dynamics and evidence handling for cases involving falsified medicines.

Strengthening Forensic and Investigative Capacity

  • Scientific evidence chain: Successful prosecution depends on forensic-driven evidence rather than mere seizure of counterfeit medications.
  • Modern forensic tools: Employ chemical and toxicological analysis, packaging forensics, ink analysis, and digital footprint mapping to detect fake drugs and counterfeit antibiotics.
  • Data intelligence: Integrate Call Detail Records (CDR) and supply-chain analytics to trace counterfeit distribution networks and improve pharmaceutical security.
  • Institutional support: Strengthen National Forensic Sciences University (NFSU) and State Forensic Laboratories to provide certification and technical training for detecting falsified medical products.
  • Forensic credibility: Multi-agency corroboration enhances evidence admissibility in courts, ensuring sustainable conviction rates in cases of counterfeit medicines.

Challenges

  • Regulatory fragmentation: Overlapping jurisdictions between health ministries, police, and financial authorities create confusion and bureaucratic delay in addressing the counterfeit drug market.
  • Limited manpower: India has fewer than 2,500 drug inspectors, far below WHO norms, to monitor an industry producing billions of doses and combat counterfeit medications.
  • Judicial bottlenecks: Lengthy court processes and weak chain of custody for evidence delay convictions in cases of fake medicine.
  • Inadequate technology: Many states lack advanced forensic facilities or digital drug traceability systems to detect falsified medicines.
  • Global trade vulnerabilities: Counterfeit medicines infiltrate through online pharmacies and unregulated export markets, escaping scrutiny and compromising pharmaceutical security.
  • Lack of consumer awareness: Patients often fail to identify spurious packaging or fake labels, weakening public vigilance against counterfeit products.
  • Corruption and collusion: Complicity between certain manufacturers, distributors, and inspectors fosters impunity in the trade of fake drugs.
  • Low deterrence: Minimal penalties and low conviction rates embolden those involved in medicine counterfeiting.
  • Policy disconnect: Absence of integration between National Drug Policy, Digital Health Mission, and law enforcement hinders cohesive action against counterfeit pharmaceutical drugs.
  • International linkages: Cross-border counterfeit networks tied to China, Myanmar, and Africa require diplomatic and intelligence collaboration to combat the global trade in falsified medical products.

Way Forward

  • Amend legal framework: Reform the Drugs and Cosmetics Act (1940) to mandate joint jurisdiction between Drug Control and Police for tackling counterfeit medicines.
  • National Anti-Counterfeit Task Force: Establish a centralised authority integrating Health, Home, Finance, and Commerce Ministries to address the counterfeit drug market.
  • Mandatory forensic testing: Every major counterfeit drug case should involve scientific validation and toxicological mapping to detect falsified medicines.
  • Financial surveillance: Integrate PMLA, GSTN, and Income Tax databases for real-time financial intelligence on counterfeit pharmaceutical drugs.
  • Technology integration: Develop a Drug Authentication and Verification App for consumers to scan and verify barcodes instantly, helping detect fake medications.
  • Pharmaceutical industry partnership: Encourage the Indian Pharmaceutical Alliance (IPA) to support traceability via blockchain or QR-based systems to enhance pharmaceutical security.
  • International cooperation: Collaborate with Interpol, WHO, and UNODC for intelligence sharing and best practices in combating counterfeit medicines globally.
  • Consumer awareness: Launch a “Know Your Medicine” campaign to educate users about fake drug indicators and how to identify counterfeit products.
  • Capacity building: Institutionalise training at NFSU and regional academies for forensic and cyber investigation of falsified medical products.
  • Accountability audit: Conduct annual audits of drug regulatory authorities’ enforcement performance across states to ensure transparency in combating counterfeit medications.

Conclusion

India’s fight against counterfeit medicines demands a science-backed, multi-agency, and legally coherent approach. Mere regulatory oversight is insufficient; the fusion of criminal law, forensic science, and financial investigation can safeguard public health, restore India’s pharmaceutical credibility, and transform enforcement into a proactive shield against medical crime and the proliferation of falsified medicines in the pharmaceutical supply chain.

Source: IE

Mains Practice Question:

“Despite being the world’s pharmacy, India faces an escalating crisis of counterfeit and substandard drugs. Discuss how integrating criminal law, financial tracking, and forensic science can strengthen India’s drug enforcement system. Suggest institutional reforms to ensure accountability and transparency in pharmaceutical regulation.”